Gensight Biologics SA GSGTF
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $0.19
- Day Range
- $0.09–0.09
- 52-Week Range
- $0.09–0.19
- Bid/Ask
- $7.35 / $9.35
- Shares Outstanding
- 234.47M
- Market Cap
- $13.89M
- Volume/Avg
- 400 / 1,251
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Gensight Biologics SA is a clinical-stage biopharma company focused on developing and commercializing gene therapies for retinal neurodegenerative diseases and central nervous system disorders. The company's pipeline leverages two core technology platforms, the Mitochondrial Targeting Sequence (MTS) and optogenetics, to help preserve or restore vision in patients suffering from blinding retinal diseases. The product candidate, LUMEVOQ, was developed using the MTS technology platform and is designed to treat LHON by restoring the function of retinal diseases resulting from mutations.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 13
Valuation
|
Metric
|
GSGTF
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
GSGTF
|
|---|---|
Quick Ratio | 0.32 |
Current Ratio | 0.39 |
Interest Coverage | −3.17 |
Quick Ratio
GSGTF
Profitability
|
Metric
|
GSGTF
|
|---|---|
Return on Assets (Normalized) | −158.76% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | — |
Return on Assets
GSGTF
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|<t#y@J | LOCK|h^BN$ | $126B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|q<Z#vy | LOCK|%bF$ | $81B | |||
| argenx SE ADR
ARGX
| LOCK|?&?Y#># | LOCK|>^ | $55B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|BF&Qn?Qz | LOCK|#tb$t | $50B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|<!<rL% | LOCK|X! | $41B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|@nqkS& | LOCK|y#TRK | $29B | |||
| Incyte Corp
INCY
| LOCK|!&>lKx | LOCK|&@ | $24B | |||
| Moderna Inc
MRNA
| LOCK|t>&t?Z | LOCK|g#$ | $24B | |||
| BioNTech SE ADR
BNTX
| LOCK|K><#w? | LOCK|^g | $24B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|&&zHrW | LOCK|Jxz | $17B |
United States